Prognostic Markers in Hematologic Oncology PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Prognostic Markers in Hematologic Oncology PDF full book. Access full book title Prognostic Markers in Hematologic Oncology by Wojciech Gorczyca. Download full books in PDF and EPUB format.
Author: Wojciech Gorczyca
Publisher: CRC Press
ISBN: 9781841845548
Category : Medical
Languages : en
Pages : 332
Get Book Here
Book Description
Effective treatment of the tumors of the hematopoietic system now often depends on an exact prognosis for the disorder concerned, and so the hematopathologist can give vital direction to the hematologic or oncologic clinician. Prognostic Markers in Hematologic Oncology comprehensively presents the numerous predictive and prognostic parameters in the practice of oncologic haematology and underlines their clinical relevance.
Author: Wojciech Gorczyca
Publisher: CRC Press
ISBN: 9781841845548
Category : Medical
Languages : en
Pages : 332
Get Book Here
Book Description
Effective treatment of the tumors of the hematopoietic system now often depends on an exact prognosis for the disorder concerned, and so the hematopathologist can give vital direction to the hematologic or oncologic clinician. Prognostic Markers in Hematologic Oncology comprehensively presents the numerous predictive and prognostic parameters in the practice of oncologic haematology and underlines their clinical relevance.
Author: Martin S. Tallman
Publisher: Springer Science & Business Media
ISBN: 0585385718
Category : Medical
Languages : en
Pages : 383
Get Book Here
Book Description
There is no field of medicine in which advances in therapy have been so closely linked to a better understanding of molecular medicine than in the area of hematologic malignancies. Diagnostic and Therapeutic Advances in Hematologic Malignancies will provide practitioners and academic clinicians with a better understanding of the constant evolving concepts in this area.
Author: Gamal Abdul Hamid
Publisher: BoD – Books on Demand
ISBN: 1789239419
Category : Medical
Languages : en
Pages : 178
Get Book Here
Book Description
The book Advances in Hematologic Malignancies presents new knowledge of cellular disease processes, molecular pathology, and cytogenetic, epigenetic, and genomic changes that have influenced the current outlook toward hematological malignancies. This book provides a unique, practical, and concise guide that is focused on the must-know points of diagnosis, prognosis, therapeutic management, and cutting edge clinical trial opportunities for each hematologic malignancy. Advances in Hematologic Malignancies is designed and organized as an essential reference source for the hematologist, hematologic oncologist, hematopathologist, and trainee.
Author: National Academies of Sciences Engineering and Medicine
Publisher:
ISBN: 9780309683494
Category :
Languages : en
Pages :
Get Book Here
Book Description
Since the late 1960s, the survival rate in children and adolescents diagnosed with cancer has steadily improved, with a corresponding decline in the cancer-specific death rate. Although the improvements in survival are encouraging, they have come at the cost of acute, chronic, and late adverse effects precipitated by the toxicities associated with the individual or combined use of different types of treatment (e.g., surgery, radiation, chemotherapy). In some cases, the impairments resulting from cancer and its treatment are severe enough to qualify a child for U.S. Social Security Administration disability benefits. At the request of Social Security Administration, Childhood Cancer and Functional Impacts Across the Care Continuum provides current information and findings and conclusions regarding the diagnosis, treatment, and prognosis of selected childhood cancers, including different types of malignant solid tumors, and the effect of those cancers on childrenâ (TM)s health and functional capacity, including the relative levels of functional limitation typically associated with the cancers and their treatment. This report also provides a summary of selected treatments currently being studied in clinical trials and identifies any limitations on the availability of these treatments, such as whether treatments are available only in certain geographic areas.
Author: Ingrid Jakobsen
Publisher: Linköping University Electronic Press
ISBN: 9176851958
Category :
Languages : en
Pages : 76
Get Book Here
Book Description
The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. Based on cytogenetic analysis, patients are divided into low risk, intermediate risk, and high-risk groups. While low risk patients have a high chance of reaching and remaining in remission after standard induction therapy, high-risk patients are likely to suffer from relapse and should be scheduled for allo-SCT when first complete remission is reached. The intermediate risk group consists of normal karyotype (NK) patients and those with karyotypes of uncertain clinical relevance, but the outcomes are heterogeneous. In NKAML patients, risk classification has improved with the addition of molecular markers including FLT3 internal tandem duplications (ITD) and mutations of NPM1 and CEBPA. Despite this development, there is a group of patients lacking reliable prognostic markers and in some cases the outcomes predicted do not match the outcomes observed, highlighting the need for additional markers. ABCB1 encodes a transporter protein responsible for the extrusion of cytotoxic compounds, including daunorubicin, over the cell membrane, and is a known resistance mechanism. Ara-C is subject to both activating and inactivating metabolic enzymes including DCK (activating), CDA and cN-II (inactivating). ABCB1, DCK, CDA and cN-II are all polymorphic, and SNPs affecting enzyme function and/or activity have potential as prognostic markers. In addition, recurrent IDH1/2 mutations lead to the expression of an enzyme with neomorphic activity associated with epigenetic alterations and disturbed differentiation. Mutations as well as a SNP in codon 105 of IDH1 have prognostic implications in AML, although the effects of different IDH mutations have been unclear. The aim of this thesis was to investigate SNPs in ABCB1 and genes associated with Ara-C metabolism, mutations in IDH1/2 and the IDH1 SNP, and their associations with treatment response and survival in AML. We show that the 1236C>T and 2677G>T SNPs in ABCB1 influence in vitro sensitivity towards AML drugs, with corresponding effects on NK-AML patient survival. These survival differences were seen mainly in patients lacking FLT3-ITD, further adding to the risk stratification. In contrast, the CDA SNPs 79A>C and -451C>T appear to influence survival mainly in FLT3-ITD positive cases. In conclusion, the above-mentioned SNPs have the potential to add important information to risk classifications especially in NK-AML patients with the ambiguous FLT3-ITD-/NPM1- or FLT3-ITD+/NPM1+ genotypes. In addition, we have shown that IDH2 R140 mutation is associated with impaired survival in AML, and that the IDH1 codon 105 SNP appears to confer a worse outcome in a subset of intermediate risk patients without FLT3-ITD. With the introduction of next generation sequencing into clinical diagnostics, IDH mutations may not only provide prognostic information but also guide the selection of patients for new drugs targeting the variant enzyme. Our results indicate that in addition to leukemia-specific mutations, constitutional SNPs may prove useful for further individualizing care-taking and should be considered when implementing these new techniques.
Author: Abeer Badr
Publisher:
ISBN: 9783659538711
Category :
Languages : en
Pages : 128
Get Book Here
Book Description
Author: Bouthaina Shbib Dabaja
Publisher: Springer
ISBN: 331942615X
Category : Medical
Languages : en
Pages : 203
Get Book Here
Book Description
This book is designed to assist practitioners in managing patients who present with difficult cases of the most common hematological malignancies. The scenarios covered are those that are likely to be encountered in patients with the various forms of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and leukemia. In each of the three sections devoted to these malignancies, multiple cases are presented. The case discussions follow a standard format. A clinical description is followed by a pathological description documenting information relevant to diagnosis and by details of staging work-up, including images. The treatment options are then discussed at length, highlighting relevant literature for each option. Finally, the treatment delivered is identified and images of the planning technique/modality used are provided. This book will be an invaluable aid to decision making for radiation oncologists and will also be of interest for hematologists.
Author: Mahul B. Amin
Publisher: Lippincott Williams & Wilkins
ISBN: 1469857960
Category : Medical
Languages : en
Pages : 2443
Get Book Here
Book Description
Knowledge in the field of urologic pathology is growing at an explosive pace. Today’s pathologists, specialists, and residents require a comprehensive and authoritative text that examines the full range of urological diseases and their diagnosis. Written by recognized leaders and educators in the field, the text provides readers with a detailed understanding of all diagnostic aspects of urological disease. Inside this unique resource, readers will explore a broad spectrum of practical information—including etiology, diagnostic criteria, molecular markers, differential diagnosis, ancillary tests, and clinical management. This is sure to be the new definitive text for urological pathology!
Author: Edward Estlin
Publisher: John Wiley & Sons
ISBN: 1444322559
Category : Medical
Languages : en
Pages : 864
Get Book Here
Book Description
This new textbook has an international authorship and is a practical, up-to-date resource for clinicians responsible for the care of children with oncologic and malignant hematologic disease. It is specifically designed for practicing oncologists and hematologists, pediatricians with an interest in childhood cancer and trainees seeking a systematic approach to these disorders. This new textbook has an emphasis on the visual presentation and ease of reading of contemporary and comprehensive information for children’s cancers and contains detailed tables, fact boxes and illustrations. The textbook begins with an introduction to the general principles of the scientific foundation and treatment of childhood cancers and hematological malignancies. Separate sections are then devoted to descriptions of central nervous system tumors, hematological malignancies and solid tumors of childhood which encompass epidemiology, cellular and molecular biology, cancer genetics, immunology, pharmacology and the findings of clinical trials. For each area of science covered, key original references and reviews are highlighted to direct further reading. Diagnostic, biological, and therapeutic issues are integrated into each tumor-specific chapter, with evidence supporting the current rationales for risk stratification and the development of novel therapies. A final section then explores supportive care, palliative care, late effects considerations and psychosocial issues as relate to children’s cancer.
Author: Julie Rowe
Publisher: McGraw Hill Professional
ISBN: 1260026639
Category : Medical
Languages : en
Pages : 528
Get Book Here
Book Description
A unique point-of-care guide to clinical hematology-oncology that answers the most frequently asked questions Hematology-Oncology Clinical Questions is the single-best resource for quickly converting the most current data and research into practical, diagnostic real-time solutions. This unique book answers more than 60 of the clinical hematology-oncology questions most commonly asked of the authors during consultation. The content flow simulates the consultation process: Question...Data...Synthesis...Solution. The initial chapters prepare you with essential background fundamentals of hematology-oncology. Subsequent chapters are divided into tumor type, beginning with solid tumor types, and then hematological malignancies. Each chapter includes: •Key Concepts•The Clinical Scenario•The Action Items•Pearls Hematology-Oncology Clinical Questions will prove to be a powerful tool to help learners from all points of the clinical spectrum understand the basic concepts of caring for a cancer patient.
